Bayer raises guidance as net income drops on YAZ risk provision
This article was originally published in Scrip
German group Bayer saw sales rise 10% in the second quarter to a record €10.18 billion, thanks in part to positive currency effects. The currency and portfolio adjusted increase was 5%. Bayer's pharmaceutical sales rose 4% (adjusted) to €2.69 billion, helped by growth in North America and China, while Western Europe declined slightly.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.